Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Current Leases: 2022-2024

Historic Current Leases for Axsome Therapeutics (AXSM) over the last 3 years, with Dec 2024 value amounting to $1.8 million.

  • Axsome Therapeutics' Current Leases rose 53.47% to $2.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.5 million, marking a year-over-year increase of 53.47%. This contributed to the annual value of $1.8 million for FY2024, which is 44.83% up from last year.
  • Axsome Therapeutics' Current Leases amounted to $1.8 million in FY2024, which was up 44.83% from $1.3 million recorded in FY2023.
  • In the past 5 years, Axsome Therapeutics' Current Leases registered a high of $1.8 million during FY2024, and its lowest value of $425,000 during FY2022.
  • Over the past 3 years, Axsome Therapeutics' median Current Leases value was $1.3 million (recorded in 2023), while the average stood at $1.2 million.
  • Data for Axsome Therapeutics' Current Leases shows a peak YoY surged of 198.12% (in 2023) over the last 5 years.
  • Axsome Therapeutics' Current Leases (Yearly) stood at $425,000 in 2022, then skyrocketed by 198.12% to $1.3 million in 2023, then spiked by 44.83% to $1.8 million in 2024.